United States - English - NLM (National Library of Medicine)

proficient rx lp - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 750 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tablets, usp and other antibacterial drugs, levofloxacin tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin tablets, usp is indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture  and  susceptibility  testing   appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to le

United States - English - NLM (National Library of Medicine)

proficient rx lp - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tablets and other antibacterial drugs, levofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin tablets are indicated for the treatment of adults (≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture andsusceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see mic

Kenya - English - Pharmacy and Poisons Board

psa international (export div. of psa chemicals &… vashi navi mumbai india - levofloxacin hemihydrate eq. to levofloxacin - film-coated tablet - levofloxacin hemihydrate eq to levofloxacin… - antibacterials for systemic use: fluoroquinolones

Canada - English - Health Canada

laboratoire riva inc. - levofloxacin (levofloxacin hemihydrate) - tablet - 250mg - levofloxacin (levofloxacin hemihydrate) 250mg - quinolones

Canada - English - Health Canada

laboratoire riva inc. - levofloxacin (levofloxacin hemihydrate) - tablet - 500mg - levofloxacin (levofloxacin hemihydrate) 500mg - quinolones

Canada - English - Health Canada

laboratoire riva inc. - levofloxacin (levofloxacin hemihydrate) - tablet - 750mg - levofloxacin (levofloxacin hemihydrate) 750mg - quinolones

United States - English - NLM (National Library of Medicine)

akorn - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 5 mg in 1 ml - levofloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: gram-positive bacteria corynebacterium species* staphylococcus aureus staphylococcus epidermidis streptococcus pneumonia streptococcus (groups c/f) streptococcus (group g) viridans group streptococci* gram-negative bacteria acinetobacter lwoffii* haemophilus influenzae serratia marcescens* * efficacy for this organism was studied in fewer than 10 infections. levofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to levofloxacin, to other quinolones, or to any of the components in this medication. pregnancy category c teratogenic effects: levofloxacin at oral doses of 810 mg/kg/day in rats caused decreased fetal body weight and increased fetal mortality. no teratogenic effect was observed when rabbits were dosed orally as high as 50 mg/kg/day, at which systemic exposure was approximately 2,250 times that observed at t

Ireland - English - HPRA (Health Products Regulatory Authority)

claris lifesciences (uk) limited - levofloxacin hemihydrate - solution for infusion - 5 milligram(s)/millilitre - fluoroquinolones; levofloxacin

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - levofloxacin hemihydrate - infusion - 5mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - levofloxacin hemihydrate - solution for infusion - 5mg/1ml